AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pyxis Oncology Announces Participation in Investor Conferences and ADC Summit
ByAinvest
Thursday, Aug 21, 2025 7:35 am ET1min read
Pyxis Oncology's CEO and CMO, Lara S. Sullivan, will participate in the Cantor Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference, with fireside chats and investor one-on-one meetings scheduled. She will also present at the 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit. Live webcasts of the Cantor and H.C. Wainwright fireside chats will be available on Pyxis Oncology's investor website.
Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, has announced that Lara S. Sullivan, M.D., President, Chief Executive Officer, and Chief Medical Officer, will participate in several upcoming conferences in September 2025.Dr. Sullivan will participate in fireside chats at the 2025 Cantor Global Healthcare Conference in New York, NY, on September 3, and the H.C. Wainwright 27th Annual Global Investment Conference in New York, NY, on September 8. Additionally, she will present at the 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit in Boston, MA, on September 9.
Live webcasts and replays of the Cantor and H.C. Wainwright fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com [1].
Pyxis Oncology, Inc. is focused on defeating difficult-to-treat cancers. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors, with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The company also initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors [2].
For more information, visit www.pyxisoncology.com or follow the company on Twitter and LinkedIn.
References:
[1] https://www.globenewswire.com/news-release/2025/08/21/3137025/0/en/Pyxis-Oncology-to-Participate-in-September-Investor-and-Industry-Conferences.html
[2] https://www.stocktitan.net/news/PYXS/pyxis-oncology-to-participate-in-september-investor-and-industry-8dhdj0lsnusa.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet